ABT-414: Additional Phase I data

Data from 44 evaluable patients with EGFR-amplified, recurrent GBM in the dose-expansion cohort of the open-label, international Phase I M12-356 trial showed

Read the full 226 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE